Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biogen Idec and Regulus Therapeutics have collaborated to investigate microRNA biomarkers for disease monitoring and response to multiple sclerosis (MS) therapy.
Subscribe to our email newsletter
According to the transaction, Biogen will invest in Regulus and make upfront and milestone payments.
Biogen corporate development executive vice president Steven Holtzman said that utilizing new technology such as biomarkers can help make more informed decisions earlier in clinical development.
"We’re excited to collaborate with Regulus to seek to identify biomarkers in MS patients, and are hopeful it can speed the work we’re doing to bring new, effective treatments to market for patients with MS," Holtzman added.
Regulus believes that microRNA biomarkers may be used to select optimal patient segments in the trials, to develop companion diagnostics, and to monitor disease progression or relapse.
Regulus Therapeutics finance chief operating officer and executive vice president Garry Menzel said, "This collaboration allows us to further explore our proprietary microRNA biomarker platform with Biogen Idec’s additional resources and expertise."